PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma
- 3 October 2017
- journal article
- letter
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (2) , 355-357
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutationsLaboratory Investigation, 2017
- Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergenceBlood, 2017
- Hodgkin lymphoma: a negative interim‐PET cannot circumvent the need for end‐of‐treatment‐PET evaluationBritish Journal of Haematology, 2016
- Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?British Journal of Haematology, 2014
- High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosisBlood, 2014
- Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugsInternational Journal of Cancer, 2013
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Lesions resembling Langerhans cell histiocytosis in association with other lymphoproliferative disorders: a reactive or neoplastic phenomenon?Human Pathology, 2006
- Simultaneous Occurrence of Hodgkin's Lymphoma and Eosinophilic Granuloma: A Potential Pitfall in Positron Emission Tomography ImagingClinical Lymphoma, 2002
- THE RELATION OF LANGERHANS CELL HISTIOCYTOSIS TO ACUTE LEUKEMIA, LYMPHOMAS, AND OTHER SOLID TUMORSHematology/Oncology Clinics of North America, 1998